HBM Healthcare Investments Backs Scipher Merger with 12.5% Chemomab Stake

summarizeSummary

HBM Healthcare Investments reports a 12.5% stake in Chemomab Therapeutics and has agreed to vote in favor of the pending reverse merger with Scipher Medicine, de-risking the deal's approval.

check_boxKey Events · Ownership and Investor Activity · CMMB

• 12.5% Stake Disclosed

  HBM Healthcare Investments (Cayman) Ltd. reports beneficial ownership of 80,971,680 ordinary shares, or 12.5% of Chemomab, including 18.2M shares via ADSs and 62.8M shares underlying pre-funded warrants exercisable within 60 days.

• Merger Support Agreement Signed

  On July 6, 2026, HBM entered into a shareholder support agreement with Scipher Medicine, committing to vote all covered shares in favor of the merger and against competing proposals, and not to transfer shares until the deal closes.

• Warrant Blocker Increased to 19.99%

  Effective September 7, 2026, HBM increased its beneficial ownership limitation on pre-funded warrants from 4.99% to 19.99%, and intends to exercise the warrants on a cashless basis to meet voting obligations.

• Merger Expected Q4 2026

  The reverse merger with Scipher Medicine is expected to close in Q4 2026, with the combined company listing on Nasdaq under ticker 'SCIP'. Chemomab shareholders will receive contingent value rights tied to nebokitug milestones.

auto_awesomeAnalysis · CMMB · Life Sciences

Just days after Chemomab Therapeutics announced a definitive reverse merger with Scipher Medicine, HBM Healthcare Investments—a Cayman-based venture capital firm—disclosed a 12.5% beneficial ownership stake, comprising 18.2 million ordinary shares via ADSs and 62.8 million ordinary shares underlying pre-funded warrants. The combined company will redomicile in the U.S. and list on Nasdaq under ticker 'SCIP'. In a move that significantly de-risks the merger vote, HBM has entered into a shareholder support agreement, committing to vote its entire stake in favor of the transaction and against any competing proposals. To fulfill these voting obligations, HBM raised its beneficial ownership blocker on the pre-funded warrants from 4.99% to 19.99%, effective September 7, 2026, and intends to exercise the warrants on a cashless basis. This alignment of a major institutional investor signals strong confidence in the deal, which is expected to close in Q4 2026. Existing Chemomab shareholders will receive contingent value rights tied to legacy asset nebokitug milestones, offering potential upside. The disclosure solidifies the merger's path forward and underscores institutional support at a critical juncture.